Nonetheless, consistent with our discoveries in scn1a zebrafish models (discussed in detail below), serotonin pathways were recently implicated as a “potential therapeutic target for DS” based on studies using SCN1A S1231R Drosophila mutants (Schutte et al., 2014). This evidence concerns the gene SCN1A and Dravet syndrome.